1/10

MASH -- formerly known as nonalcoholic steatohepatitis (NASH) -- is a risk factor for the following medical condition:

  • Asthma 
  • Cardiovascular disease
  • Arthritis
  • Osteoporosis
2/10

Kids younger than 10 can have liver inflammation and damage. True or False? 

  • True
  • False
3/10

Along with genetics, the following raises your risk of developing MASH if you already have MASLD.

  • Kidney failure 
  • Insulin resistance
  • Recurrent gallstones
  • Prior heart attack or stroke
4/10

You’re more likely to develop MASH if you have a diet high in this nutrient:

  • Omega-6 fats
  • Fructose 
  • Animal protein
  • Complex carbohydrates
5/10

Liver failure from cirrhosis is the most common cause of death for people who have MASH. True or False?

  • True
  • False
6/10

Losing weight can help reduce fat in your liver, but it can’t reverse inflammation related to MASH. True or False?

  • True
  • False
7/10

MASH is more common in women or people assigned female at birth who: 

  • Still have a regular menstrual cycle
  • Are perimenopausal 
  • Are postmenopausal 
8/10

If you have MASH, this is the No. 1 predictor of future liver-related health problems: 

  • Your degree of liver scarring
  • How much inflammation you have
  • If you have a high body mass index
  • How long you’ve had fatty liver 
9/10

There’s no drug treatment approved to treat MASH. True or False?

  • True
  • False
10/10

If you have MASH, a blood test can show if you have inflammation or scarring in your liver. True or False?

  • True
  • False

Show Sources

IMAGE PROVIDED BY:

  1. Science Photo Library/Getty Images 

 

SOURCES: 

Arteriosclerosis, Thrombosis, and Vascular Biology: “Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.” 

National Institute of Diabetes and Digestive and Kidney Diseases: “Definition & Facts of NAFLD & NASH in Children,” “Insulin Resistance & Prediabetes.” 

Clinical Liver Disease: “Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease.” 

Columbia University Irving Medical Center: “What Parents Should Know About Kids and Fatty Liver Disease.” 

Clinical and Molecular Hepatology: “Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.” 

Diabetes Spectrum: “Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People with Type 2 Diabetes: From Bench to Patient Care.” 

Frontiers in Pharmacology: “The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease.”

Yale Medicine: “FDA Approves Rezdiffra, the First Drug for NASH, a Form of Fatty Liver Disease.” 

HealthyWomen.org: “Fast Facts: What You Need to Know About Fatty Liver Disease.”

Euroasian Journal of Hepato-Gastroenterology: “Gender Differences in Nonalcoholic Fatty Liver Disease.” 

Liver International: “Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).” 

Therapeutic Advances in Endocrinology and Metabolism: “Non-pharmacological management options for MAFLD: a practical guide.” 

Cleveland Clinic: “Metabolic Dysfunction-Associated Steatohepatitis.” 

Scientific Reports: “An explainable machine learning model for prediction of high-risk nonalcoholic steatohepatitis.” 

FDA: “FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease.” 

Revista de Gastroenterologia del Peru: “Normal transaminases in obese patients with metabolic associated steatohepatitis (MASH): a cohort of Peruvian patients.” 

Tinsay Ambachew Woreta, MD, MPH, program director, gastroenterology and transplant hepatology fellowships; assistant professor of medicine, Johns Hopkins University School of Medicine. 

National Institute of Diabetes and Digestive and Kidney Diseases: “Insulin Resistance & Prediabetes.”